百心安－Ｂ (2185.HK)

3.200 -0.030 (-0.93%) 收市：03:28PM HKT

百心安－Ｂ

Building 4
Room 302, 3rd Floor No.590 Ruiqing Road E. Zhangjiang Hi-Tech Park, Pudong New A
Shanghai
China
86 21 6879 8511
https://www.bio-heart.com

版塊: Healthcare
行業: Biotechnology
全職員工: 58

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Li Wang	Exec. Chairman, CEO & GM	101.29k	無	1968
Mr. Yunqing Wang	CFO, Joint Company Sec. & Exec. Director	171.66k	無	1985
Ms. Peili Wang	Financial Mang. & Exec. Director	19.93k	無	1984
Dr. Bradley Stewart Hubbard D.V.M., DVM	Chief Medical Officer	無	無	1959
Ms. Siu Ying Kwok	Joint Company Sec.	無	無	1985
Mr. Tao Cai	Supervisor & Head of Technology of BRS	無	無	1987

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 HKD。

描述

Shanghai Bio-heart Biological Technology Co., Ltd. operates as an interventional cardiovascular device company in the People's Republic of China. The company focuses on the provision of bioresorbable scaffolds (BRS) and renal denervation (RDN) therapies for the treatment of coronary artery diseases and uncontrolled and resistant hypertension. It is developing Bioheart, a BRS system used in percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis 2nd, a multi-electrode RDN product candidate; and drug coated balloon, a sirolimus drug-eluting balloon catheter designed for instent restenosis. The company has collaboration agreements with Terumo (China) Investment Co., Ltd. to conduct clinical trials for Iberis 2nd. Shanghai Bio-heart Biological Technology Co., Ltd. was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

公司管治

截至 無 止，百心安－Ｂ 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。